JACC: CardioOncology - Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitors Trials
Episode Description
Commentary by Corralea Kappel
We use cookies to run this site. Analytics cookies, which show us how it's used, stay off unless you accept them. Change your mind any time with the cookie button at the bottom right. How we use cookies